Print the page
Increase font size
Biogen Breaks Through 5-Year Stalemate

Posted June 09, 2021

Biogen Breaks Through 5-Year Stalemate

In response to my friend’s unemployment insurance predicament, a reader says: “Typical government thinking. They penalize a small business that did the right thing by keeping all their employees working.

“The federal government creates a problem, and then asks others to pay for it.”

Another reader references the American Rescue Plan…

“I found this most interesting since the whole purpose of the federal government stimulus money to states was to cover these UI costs.

“So what did states do with the money if they didn't apply it to the unemployment fund as stipulated? I think Maryland has some ‘splainin to do, don't you?”

Indeed, reader. We’ll cover that Friday…

Send your opinions to, TheRundownFeedback@StPaulResearch.com.

Your Rundown for Wednesday, June 9, 2021…

Biogen’s Big Step Forward…

“This could be a key moment for the biotech sector,” says our chief market analyst Greg Guenthner.

Of course, Greg’s talking about the market’s big mover Monday -- Biogen Inc. -- and BIIB’s breakneck ascent, jumping more than 50%, after the company received FDA approval for its Alzheimer drug Aduhelm.

“Results from clinical trials of Aduhelm were mixed,” Reuters says, “but the drug was shown to reduce amyloid beta plaques in the brain, which is likely to benefit patients.”

To give an idea how important this drug is, there hasn’t been an approved Alzheimer’s treatment since 2003… for a disease that’s the sixth leading cause of death in the U.S.

"We've not had a disease modifying therapy approved ever," says Alzheimer’s specialist Dr. Ronald Petersen of the Mayo Clinic. But he warns: "This is not a cure. It's hoped that this will slow the progression of the disease."

A step forward in the fight against Alzheimer’s Disease might be a step forward for an entire stock sector…

“This could be a key moment for the biotech sector,” Greg says, “especially when you consider that BIIB stock has gone essentially nowhere since 2015!

“BIIB has been dead money for more than five years,” he adds. “In fact, biotech as a sector has been a laggard ever since it flamed out during the stealth bear market of 2015–16.”

Greg’s takeaway? “Perhaps we finally see a sustained post-pandemic run in biotech. It’s long overdue -- and worth watching closely for trading opportunities moving forward.”

Market Rundown for Wednesday, June 9, 2021

The S&P 500 Index is up 6.5 points to 4,232… approaching record highs.

Oil is up 0.5% to $70.41 for a barrel of West Texas Intermediate.

Gold is up $3.30 to $1,898.10 per ounce.

Bitcoin is up 6.45% to $34,969.50.

Send your comments and questions to, TheRundownFeedback@StPaulResearch.com.

We’ll be back Friday; have a good one!

For The Rundown,

Aaron Gentzler

Aaron Gentzler
Editor, The Rundown
TheRundownFeedback@StPaulResearch.com

$1,000 Sign Up Bonus To Work Part-Time at an Arcade

Posted June 18, 2021

By Aaron Gentzler

Today we take a look at Ford’s recent run of good fortune and forecast what could come next for the stock. We also feature a reader letter about wages and the free market.
A Meme Stock ETF

A Meme Stock ETF

Posted June 16, 2021

By Aaron Gentzler

We think an ETF pegged exclusively to meme stocks must be in the works. We’re calling it now…

Novavax: Competitive Advantages ‘Boost’ Profits

Posted June 14, 2021

By Aaron Gentzler

Novavax announced its Covid-19 vaccine… So what’s next for the Maryland-based biotech company?
Small Business Taxed for Pandemic Shortfalls

Small Business Taxed for Pandemic Shortfalls

Posted June 07, 2021

By Aaron Gentzler

Small businesses -- hanging on by a thread -- are being taxed for pandemic shortfalls…
Trump and Biden’s “Rare” Agreement

Trump and Biden’s “Rare” Agreement

Posted June 04, 2021

By Aaron Gentzler

“Trump and Biden don’t agree on much,” says our tech expert Ray Blanco. “So what’s bringing together both sides of the aisle?”
   When It Costs Too Much…

When It Costs Too Much…

Posted June 02, 2021

By Aaron Gentzler

Over the past 15 months, pharmaceutical companies have become keenly aware of China’s dominance…